Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study

被引：0

作者：

Hartung, Hans-Peter ^{[1
,2
,3
,4
]}

Steinman, Lawrence ^{[5
]}

Bar-Or, Amit ^{[6
,7
]}

Sheffield, James ^{[8
]}

Cheng, Chun-Yen ^{[8
]}

Riolo, Jon ^{[8
]}

Harris, Sarah ^{[8
]}

Reardon, Jennifer ^{[8
]}

Thorpe, Andrew ^{[8
]}

Cree, Bruce A. C. ^{[9
]}

机构：

[1] Heinrich Heine Univ, Fac Med, Dusseldorf, Germany

[2] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[3] Med Univ Vienna, Dept Neurol, Vienna, Austria

[4] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic

[5] Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Stanford, CA USA

[6] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA USA

[7] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA USA

[8] Bristol Myers Squibb, Princeton, NJ USA

[9] Univ Calif San Francisco, Dept Neurol, Weill Inst Neurosci, San Francisco, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P1606/503

引用

页码：1016 / 1017

页数：2